Grants are sums of money given to help further the goals of small businesses or individuals. They can be awarded by government entities or private businesses. Unlike a loan, grants do not need to be repaid.
428 grants found
The purpose of the NIH Blueprint and BRAIN Initiative Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award is to support a defined pathway across career stages for outstanding graduate students from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences.
The NICHD Small Research Grant Program (R03 Clinical Trial Required) supports clinical trials that fall within the NICHD mission. The R03 activity code supports small research projects that can be carried out in a short period of time with limited resources.
The NICHD Small Research Grant Program (Clinical Trial Required) supports clinical trials that fall within the NICHD mission. This funding opportunity announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.”
This Notice of Special Interest (NOSI) rescinds and replaces NOT-NS-20-089 (Notice to Encourage Eligible NINDS Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) Initiative Awardees to Apply for PA-20-222 "Research Supplements to Promote Diversity in Health-Related Research").
A growing body of drug and alcohol research has been reporting outcomes that vary by sex across all domains of research, including basic, translational and clinical, resulting in a growing number of literature reviews.
The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing.
This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor.
NIH recognizes that the high cost of childcare impacts graduate students and post-doctoral researchers funded through NIH fellowships, and their ability to successfully complete their training and fully participate in the extramural research workforce.
Treating injured and traumatized children and efforts to implement preventive interventions have become increasingly challenging in the context of the current pandemic. Children are notably at greater risk of injury, morbidity and mortality due to the social isolation, economic stressors, and other challenges related to policies and practices designed to mitigate the spread of the coronavirus.
The objectives of this NOSI are to advance knowledge of the gynecologic care, preconception health, pregnancy, and parenting experiences of WWD; to reduce barriers to inclusion in meaningful reproductive health, pregnancy, and parenting experiences among WWD; and to improve outcomes in reproductive health, pregnancy, and parenting for WWD and their children.
This Notice of Special Interest informs current awardees of National Cancer Institute (NCI) cancer prevention and symptom management clinical trial grants of an opportunity for supplemental funding of eligible NCI-supported grant and cooperative agreement awards so that awardees can undertake and evaluate recruitment and retention strategies and thereby facilitate the success of their clinical trial programs.
The purpose of this Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is to encourage research that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function.
The purpose of this Funding Opportunity Announcement (FOA) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems.
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from Small Business Concerns (SBCs) to pursue translational activities and small clinical studies to advance the development of therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems.
This funding opportunity announcement (FOA) encourages applications from small business concerns (SBCs) for Small Business Innovation Research (SBIR) projects to facilitate the design, creation, and implementation of novel tools and devices for the health and management of research animals, and to advance equipment that improves the operation and environmental conditions of animal facilities that support biomedical and bio-behavioral research.
This funding opportunity announcement (FOA) encourages applications from small business concerns (SBCs) for Small Business Technology Transfer (STTR) projects to facilitate the design, creation, and implementation of novel tools and devices for the health and management of research animals, and to advance equipment that improves the operation and environmental conditions of animal facilities that support biomedical and bio-behavioral research.
There are several known factors or exposures across neonatal, early childhood, and adolescent development that influence the risk of SUD. These include genetic factors; and environmental factors such as exposures to drugs and/or toxins; nutrition; adverse gestational and perinatal conditions; resource scarcity; neglect; and trauma.
The purpose of this notice is to encourage research project submissionsthat leverage whole-brain or large connectome resources in genetically tractable model organisms to investigate the role of distributed neuronal circuits in behaviors relevant to substance use disorders (SUD).
This announcement encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, cannabis, tobacco, prescription drugs, and other substances.
This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies.